Back to search

Article

512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies

2021-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2836b077-55fc-5948-b469-ca46ae802c34
DOI
10.1016/j.annonc.2021.08.1034
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignanciesDOI 10.1016/j.annonc.2021.08.1034
34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trialSemantic proximity
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.Semantic proximity
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1ASemantic proximity
Targeting ATR in patients with cancerSemantic proximity
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsSemantic proximity
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response DefectsSemantic proximity
Targeting ATR in cancerSemantic proximity
The DNA damage response to ATR inhibitionSemantic proximity
Potential therapeutic targets in ARID1A-mutated cancers.Semantic proximity
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors.Semantic proximity
Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation.Semantic proximity
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Semantic proximity
Select a neighboring publication to make it the new centre.